Events & Presentations

2023 uniQure N.V. Annual General Meeting — June 13, 2023

Proxy Statement

Proxy Card

Proxy Notice

ARS Form 10K

IFRS Annual Report 

Upcoming Webcasts

No webcasts scheduled. Check back soon.

Webcast Archive

  • Guggenheim Genomics Medicine and Rare Disease Days
    2:45PM ET to 3:10PM ET

    View Webcast
  • 2023 Stifel Virtual CNS Days
    11:30AM ET to 11:55AM ET

    View Webcast
  • 43rd Annual TD Cowen Health Care Conference
    10:30AM ET to 11:30AM ET

    View Webcast
  • uniQure’s Virtual Research & Development Event
    8:30AM ET to 10:30 AM ET

    View Webcast

Investor Presentations

  • April 2023 Corporate Presentation – Investor Presentation

    View Presentation
  • Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements

    View Presentation
  • ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions

    View Presentation
  • EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia B

    View Presentation
  • ESGCT 2022 – linQURE™ platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disorders

    View Presentation
  • ISTH 2021 – Clinical Outcomes in Adults with Hemophilia B With Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the HOPE-B Trial

    View Presentation
  • ESGCT 2022 – AAV-miQURE®-mediated targeting of hexanucleotide repeat expansion-containing transcripts in ALS C9orf72 mouse models

    View Presentation
  • Gene Therapy Information

    View Presentation
  • ESGCT 2022 – Overexpressing a protective variant while simultaneously lowering toxic APOE as potential treatment for Alzheimer Disease

    View Presentation
  • ESGCT 2022 – Development of a novel AAV9 gene therapy for the treatment of temporal lobe epilepsy using animal model and human organotypic slices

    View Presentation
  • ESGCT 2022 – Biodistribution and safety of a novel AAV9 gene therapy for treatment of temporal lobe epilepsy shown in non-human primates

    View Presentation
  • ESGCT 2022 – Scale-down of AAV production from commercial scale to a high-throughput mini-bioreactor system

    View Presentation
  • ESGCT 2022 – Impact of bioreactor control parameters on AAV production

    View Presentation
uniQure Logo Twitter Icon LinkedIn Icon YouTube Icon Twitter Icon Arrow Slideshow Next Button